Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059226 | 0.90 | STS (0.60) | STSTMPRSS11DP2RX7YAP1 | |
| SCHEMBL10058290 | 0.80 | TMPRSS11D (0.59) | STSTMPRSS11D | |
| SCHEMBL12969028 | 0.79 | STS (0.54) | STSTMPRSS11DMEN1KMT2AMAPT | |
| SCHEMBL12969029 | 0.79 | STS (0.54) | STSTMPRSS11DMEN1KMT2AMAPT | |
| SCHEMBL12969037 | 0.78 | TMPRSS11D (0.49) | STSTMPRSS11D | |
| SCHEMBL19390407 | 0.78 | TMPRSS11D (0.49) | STSTMPRSS11D | |
| SCHEMBL10058280 | 0.77 | CASP1 (0.50) | — | |
| SCHEMBL1842426 | 0.77 | MEN1 (0.61) | STSMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL19390361 | 0.76 | STS (0.47) | STSTMPRSS11DKMT2A | |
| SCHEMBL19390362 | 0.76 | STS (0.47) | STSTMPRSS11DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655399-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012083436-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | F2, F12, SERPINC1 | STS 54/4885TMPRSS11D 49/4885MEN1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.